GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead Sciences (GILD) reported strong Q2 2025 results, with adjusted EPS of $2.01 and revenue of $7.1 billion both exceeding analyst estimates, leading to a 7.3% stock increase and raised full-year guidance. This outperformance was driven by robust growth in its HIV franchise, notably Biktarvy and Descovy, and the recent approval of the long-acting PrEP drug Yeztugo, which is expected to further bolster future HIV sales despite declines in Cell Therapy and Liver Disease segments. The company's strong cash position supports its dividend and ongoing pipeline development, positioning it for continued growth in its core areas.

Analysis

Gilead Sciences reported a strong second quarter for 2025, with adjusted EPS of $2.01 and revenue of $7.1 billion surpassing consensus estimates and triggering a 7.3% stock increase. This performance prompted the company to raise its full-year 2025 guidance, driven primarily by the outperformance of its HIV franchise, which saw sales grow 7% year-over-year. The growth was led by the flagship drug Biktarvy, with sales up 9% to $3.5 billion, and Descovy, which grew 35% to $653 million. The recent FDA approval of Yeztugo, a long-acting injectable PrEP drug, is a significant strategic development expected to fortify Gilead's market leadership against generic competition and rivals like GSK. While the oncology drug Trodelvy also showed strong momentum with a 14% sales increase to $364 million, these gains were partially offset by material headwinds in other segments. The Cell Therapy franchise experienced a 7% sales decline to $485 million due to competitive pressures, and the Liver Disease portfolio dropped 4% to $795 million, impacted by Medicare Part D pricing changes. Despite these challenges, Gilead's financial position remains robust, with $7.1 billion in cash supporting a $994 million dividend payout and $527 million in share repurchases in the quarter, underpinning a sustainable 2.67% yield.

Key Decisions for Investors

• Existing shareholders may consider holding their positions to capitalize on the attractive 2.67% dividend yield and ongoing share repurchase program, which are well-supported by the company's strong cash flow.
• Prospective investors should exercise caution, as the stock is trading near its 52-week high after a 28.2% year-to-date gain, and may want to monitor for a more favorable entry point despite the positive operational momentum.
• Investors should closely track the commercial launch and market uptake of the new HIV drug Yeztugo, as its success is a critical catalyst needed to justify the current valuation and offset persistent revenue declines in the Cell Therapy and Liver Disease franchises.